Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical features, treatment, and follow-up of OPPG and high-bone-mass disorders: LRP5 is a key regulator of bone mass.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA - 1 Aug 2024

Ren Na, Lv Shanshan, Li Xiang, Shao Chong, Wang Ziyuan, Mei Yazhao, Yang Wendi, Fu Wenzhen, Hu Yunqiu, Sha Ling, Hu Weiwei, Zhang Zhenlin, Wang Chun

Abstract excerpt

Osteoporosis-pseudoglioma syndrome (OPPG) and LRP5 high bone mass (LRP5-HBM) are two rare bone diseases with opposite clinical symptoms caused by loss-of-function and gain-of-function mutations in LRP5. Bisphosphonates are an effective treatment for OPPG patients. LRP5-HBM has a benign course, and age-related bone loss is found in one LRP5-HBM patient. PURPOSE: Low-density lipoprotein receptor-related protein 5...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bone Density
Share to Bone Density Conservation Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Diphosphonates

Share to Follow-Up Studies

Share to Low Density Lipoprotein Receptor-Related Protein-5

Share to Osteogenesis Imperfecta

Share to Young Adult

Source

Open in PubMed Open full text

Identifiers

PMID: 38625381
DOI: 10.1007/s00198-024-07080-x
PMCID: PMC11281985

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical features, treatment, and follow-up of OPPG and high-bone-mass disorders: LRP5 is a key regulator of bone mass.PMID 38625381Read ↗

Osteoporosis-pseudoglioma syndrome: three novel mutations in the LRP5 gene and response to bisphosphonate treatment.Semantic proximity Read ↗

Pathogenic mutations and polymorphisms in the lipoprotein receptor-related protein 5 reveal a new biological pathway for the control of bone mass.Semantic proximity Read ↗

LRP receptor family member associated bone disease.Semantic proximity Read ↗

The genetics of low-density lipoprotein receptor-related protein 5 in bone: a story of extremes.Semantic proximity Read ↗

A family with osteoporosis pseudoglioma syndrome due to compound heterozygosity of two novel mutations in the LRP5 gene.Semantic proximity Read ↗

Contrasting LRP5 Mutations in Osteoporosis-Pseudoglioma Syndrome and Osteopetrosis: Case Reports and Literature Review.Semantic proximity Read ↗

Atypical femoral fracture in osteoporosis pseudoglioma syndrome associated with two novel compound heterozygous mutations in LRP5.Semantic proximity Read ↗

[Osteoporosis-pseudoglioma Syndrome: a pediatric case of primary osteoporosis].Semantic proximity Read ↗

Clinical and molecular findings in osteoporosis-pseudoglioma syndrome.Semantic proximity Read ↗

Novel mutation in LRP5 gene cause rare osteosclerosis: cases studies and literature review.Semantic proximity Read ↗

Novel Homozygous LRP5 Mutations in Mexican Patients with Osteoporosis-Pseudoglioma Syndrome.Semantic proximity Read ↗

Novel Homozygous Nonsense Mutation in the LRP5 Gene in Two Siblings with Osteoporosis-pseudoglioma SyndromeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.